PMID: 9535594Apr 16, 1998Paper

Circumvention of multidrug resistance in genitourinary tumors

International Journal of Urology : Official Journal of the Japanese Urological Association
J P van Brussel, G H Mickisch

Abstract

Chemotherapy is the principal strategy to systemically challenge metastasized cancers of genitourinary origin. Unfortunately, the efficacy of chemotherapy is often hampered by multidrug resistance, the resistance to a variety of structurally and functionally distinct cytotoxic agents. Multidrug resistance can be either intrinsic or acquired, and can be caused by several mechanisms. The so-called classical multidrug resistance, mediated by the MDR1 gene product P-glycoprotein, has been held mainly responsible for inferring the multidrug resistance phenotype on urologic malignancies. However, several other multidrug resistance pathways have been identified. Multidrug resistance can be caused by the membrane-bound multidrug-resistance-associated protein, the detoxifying glutathione metabolism, the antiapoptotic protein BCL2, and changes in levels or activity of the topoisomerase enzymes. Strategies to overcome multidrug resistance of genitourinary tumors have arisen from the better understanding of the biologic and molecular mechanisms of multidrug resistance, and have been studied in experimental and clinical settings. However, attempts to modulate multidrug resistance in clinical renal cell, bladder, prostate, and testicular can...Continue Reading

References

Jul 1, 1992·Cancer·C Mahler, L Denis
Jan 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·G H MickischI Pastan
Jun 1, 1991·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G SchwartsmannF Segal
Apr 1, 1991·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C J RodenburgJ Verweij
Jan 1, 1991·Scandinavian Journal of Urology and Nephrology·O LukkarinenU Tidefeldt
Jan 18, 1989·Journal of the National Cancer Institute·L J GoldsteinG M Brodeur
Mar 1, 1986·European Journal of Cancer & Clinical Oncology·C A PresantL Green
Aug 1, 1986·International Journal of Radiation Oncology, Biology, Physics·D GloverS Vogl
Oct 1, 1995·The Journal of Pathology·G I MurrayM D Burke
Aug 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerJ P O'Brien
Jun 1, 1995·American Journal of Clinical Oncology·E WarnerK L Skorecki
Jan 1, 1994·The Journal of Urology·J ParkH B Grossman
Feb 1, 1994·The Journal of Urology·M J SiegsmundM M Gottesman
May 4, 1994·Journal of the National Cancer Institute·L A SpeicherK D Tew
Jun 1, 1994·International Journal of Cancer. Journal International Du Cancer·I BashirC S Foster
Nov 22, 1994·Proceedings of the National Academy of Sciences of the United States of America·W H LeeW G Nelson
Jul 1, 1993·British Journal of Cancer·A KatagiriS Sato

❮ Previous
Next ❯

Citations

Aug 6, 2003·Critical Reviews in Oncology/hematology·J BellmuntJ Baselga
Feb 12, 2011·Journal of Photochemistry and Photobiology. B, Biology·Yun-Mi JeongDong-Seok Kim
Jul 28, 2007·Pharmacotherapy·Cheryl A Grandinetti, Barry R Goldspiel
Oct 8, 1999·International Journal of Urology : Official Journal of the Japanese Urological Association·S NaitoH Koga
May 25, 2002·International Journal of Urology : Official Journal of the Japanese Urological Association·Koji SatoMikio Namiki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.